Prof Fred Saad speaks to ecancer about the efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications from the ARANOTE post hoc analyses.

In this video, Prof Saad breaks down findings from the phase three ARANOTE trial evaluating darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

The analysis shows that darolutamide significantly improved radiological progression-free survival compared with placebo, with consistent benefit across patients regardless of the number or type of comorbidities or concomitant medications.

This included patients with common conditions such as cardiovascular, metabolic, renal, and musculoskeletal disorders.

Importantly, treatment was well tolerated across all subgroups, with similar rates of adverse events and fewer treatment discontinuations compared with placebo, even among patients with higher comorbidity burden or medication use.

Prof Saad highlights that these results support darolutamide as a reliable and broadly applicable treatment option, including for patients with complex medical profiles often seen in real-world clinical practice.